Conference Coverage

Adalimumab strikes out for aortic inflammation in psoriasis

 

Key clinical point: Adalimumab does not appear to reduce aortic inflammation in psoriasis, a risk factor for cardiovascular events.

Major finding: After a year of treatment, patients had no change in aortic inflammation, compared with placebo and baseline.

Study details: Randomized, controlled trial of 97 patients

Disclosures: The National Institutes of Health and AbbVie, adalimumab’s maker, funded the work. Among many industry ties, Dr. Gelfand is a consultant for Janssen, maker of ustekinumab, and receives research grants from Janssen and AbbVie.

Source: Gelfand JM et al. IID 2018, abstract 393


 

REPORTING FROM IID 2018

The work was funded by the National Institutes of Health and AbbVie, adalimumab’s maker. Among many industry ties, Dr. Gelfand is a consultant for Janssen, maker of ustekinumab, and receives research grants from Janssen and AbbVie.

SOURCE: Gelfand JM et al. IID 2018, Abstract 393.

Next Article: